



THE JOURNAL OF CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study

Author(s): Akira Iwanami, MD, PhD; Kazuhiko Saito, MD, PhD; Masakazu Fujiwara, PhD; Daiki Okutsu, MS; and Hironobu Ichikawa, MD, PhD

DOI Number: <https://doi.org/10.4088/JCP.19m12979>

List of Supplementary Material for the article

1. [Figure 1](#) Change From Baseline in ADHD-RS-IV With Adult Prompts Total Scores (A), Inattention Subscale Scores (B), and Hyperactivity-Impulsivity Subscale Scores (C)

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Figure 1. Change From Baseline in ADHD-RS-IV With Adult Prompts Total Scores (A), Inattention Subscale Scores (B), and Hyperactivity-Impulsivity Subscale Scores (C)

Data are from MMRM analyses in the full analysis set.

*Difference vs placebo (LS mean [95% CI] and *P* value) is presented only at time points where the difference was statistically significant (*P* < .05).

Abbreviations: ADHD-RS-IV = Attention-Deficit/Hyperactivity Disorder-Rating Scale IV; CI = confidence interval; GXR = guanfacine extended-release; LS = least squares; MMRM = mixed model for repeated measures; SD = standard deviation; SE = standard error.

